Trial record 1 of 1 for:
XPORT-DLBCL-025
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04607772 |
|
Recruitment Status :
Recruiting
First Posted : October 29, 2020
Last Update Posted : February 2, 2021
|
Sponsor:
Karyopharm Therapeutics Inc
Information provided by (Responsible Party):
Karyopharm Therapeutics Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase 1/2, multicenter, open-label study to evaluate the efficacy, and safety of various combinations with selinexor in participants with RR DLBCL. The study will be conducted in two phases: Phase 1 and 2. The Phase 1 of the study will be a standard 3 + 3 dose escalation to determine the maximal tolerated dose (MTD), recommended Phase 2 dose (RP2D) for each treatment arm, and assess the dose limiting toxicities (DLTs). The Phase 2 of the study will be a dose expansion study to assess the efficacy and safety of for RP2D selected at the end of Phase 1 of the study for each treatment arm.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Drug: Selinexor Drug: Rituximab Drug: Bendamustine Drug: Polatuzumab Vedotin Drug: Ibrutinib Drug: Lenalidomide Drug: Tafasitamab Drug: Venetoclax Drug: Gemcitabine Drug: Oxaliplatin | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 308 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) |
| Actual Study Start Date : | November 18, 2020 |
| Estimated Primary Completion Date : | December 2025 |
| Estimated Study Completion Date : | December 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Lymphoma
Drug Information available for:
Selinexor
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm A: Selinexor with Bendamustine and Rituximab (S-BR))
Participants will receive a dose of 40 or 60 or 80 milligrams (mg) of selinexor oral tablets once weekly on Days 1, 3, and 8 for Cycle 1 up to 6 (each cycle consists of 21 days) during primary treatment and on Days 1, 8, 15, 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an intravenous (IV) dose of bendamustine 90 milligram per square meter (mg/m^2) on Days 1 and 2 and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Bendamustine Dose: 90 mg/m^2 |
|
Experimental: Arm B: Selinexor with Polatuzumab Vedotin and Rituximab (S-PR)
Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1, 3, and 8 for Cycle 1 up to 6 (each cycle consists of 21 days) during primary treatment and on Days 1, 8, 15, 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 milligram per kilogram (mg/kg) and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Polatuzumab Vedotin Dose: 1.8 mg/kg |
|
Experimental: ArmC: Selinexor, Polatuzumab Vedotin, Bendamustine, Rituximab (S-PBR)
Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1, 3, and 8 for Cycle 1 up to 6 (each cycle consists of 21 days) during primary treatment and on Days 1, 8, 15, 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 mg/kg and IV dose of rituximab 375 mg/m^2 on Day 1, and IV dose of bendamustine 90 mg/m^2 on Days 1 and 2 during primary treatment.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Bendamustine Dose: 90 mg/m^2 Drug: Polatuzumab Vedotin Dose: 1.8 mg/kg |
|
Experimental: Arm D: Selinexor, Rituximab, Gemcitabine, Oxaliplatin (S-R-GemOx)
Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1 and 3 for Cycle 1 up to 6 (each cycle consists of 14 days ) during primary treatment and on Days 1, 8, 15, 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2, IV dose of gemcitabine 1000 mg/m^2, and Oxaliplatin IV dose of 100 mg/m^2 on Day 1 during primary treatment.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Gemcitabine Dose: 1000 mg/m^2 Drug: Oxaliplatin Dose: 100 mg/m^2 |
|
Experimental: Arm E: Selinexor with Ibrutinib and Rituximab (S-IR)
Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1, 8, and 15 for Cycle 1 up to 6 during primary and continuous treatment (each cycle consists of 28 days). participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and ibrutinib oral dose of 420 or 560 mg on Day 1 to 28 during primary treatment. Participants will also receive ibrutinib oral dose of 420 mg daily during continuous treatment.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Ibrutinib Dose: 420, 560 mg |
|
Experimental: Arm F: Selinexor with Lenalidomide and Rituximab (S-LR)
Participants will receive a dose of 40 or 60 mg of selinexor oral tablets once weekly on Days 1, 8, and 15 for Cycle 1 up to 6 during primary and continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and lenalidomide oral dose of 20 mg once daily on Days 1 to 21 during primary treatment. Participants will also receive lenalidomide oral dose of 20 mg on Days 1 to 21 during the continuous treatment.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Rituximab Dose: 375 mg/m^2 Drug: Lenalidomide Dose: 20, 25 mg |
|
Experimental: Arm G: Selinexor with Lenalidomide and Tafasitamab (S-LT)
Participants will receive a dose of 40 or 60 mg of selinexor oral tablets once weekly on Days 1, 8, and 15 for Cycle 1 up to 3 during primary treatment and Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days per cycle). During the primary treatment (Cycle 1 to 12), participants will also receive lenalidomide oral dose of 25 mg once daily on Days 1 to 21, tafasitamab IV dose of 12 mg/kg on Days 1, 8, 15, and 22 for Cycle 1 to 3 and Days 1 and 15 for Cycle 4 to 12. Participants will also receive an IV dose of tafasitamab 12 mg/kg during the continuous treatment on Days 1 and 15.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Lenalidomide Dose: 20, 25 mg Drug: Tafasitamab Dose: 12 mg/kg |
|
Experimental: Arm H: Selinexor with Venetoclax (S-V)
Participants will receive 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1, 8 and 15 for Cycle 1 up to 6 of primary and continuous with treatment duration (28 days per cycle). Participants who receive 40 and 60 mg of selinexor during primary treatment will also receive oral dose of venetoclax 200 mg on Days 1 to 7 then 400 mg on Days 8 to 28 for cycle 1; 400 mg daily for Cycle 2 to 6 (each cycle=28 days). Participants who receive 60 and 80 mg of selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7 then 600 mg on Days 8 to 28 for Cycle 1; 600 mg daily for Cycle 2 to 6 (each cycle=28 days). Participants who receive 80 mg selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7, then 600 mg from Days 8 to 14, then 800 mg from Day 15 to 28 for Cycle 1; 800 mg daily for Cycle 2 to 6 (each cycle=28 days). Participants during continuous treatment will also receive venetoclax 400 mg orally daily.
|
Drug: Selinexor
Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
Other Name: KPT-330 Drug: Venetoclax Dose: 200, 400, 600, 800 mg |
Primary Outcome Measures :
- Phase 1: Maximum Tolerated Dose (MTD) [ Time Frame: Within the first cycle (maximum 28 days) of treatment ]
- Phase 1: Recommended Phase 2 Dose (RP2D) [ Time Frame: Up to 6 cycles (up to 6 months) of treatment ]
- Phase 2: Overall Response Rate (ORR) per the Lugano Classification 2014 [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months) ]
Secondary Outcome Measures :
- Phase 1: Overall Response Rate per the Lugano Classification 2014 [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months) ]
- Phase 1: Disease Control Rate (DCR) per Lugano Classification 2014 [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a CR or PR or stable disease (SD) (up to 6 months) ]
- Phase 1: Duration of Response (DOR) per Lugano Classification 2014 [ Time Frame: Time from the first response of PR or CR until disease progression (up to 12 months) ]
- Phase 1: Overall Response Rate (ORR) per the Modified Lugano Classification [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a CR or PR (up to 6 months) ]
- Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity [ Time Frame: From start of study drug administration up to 30 days after last dose of study treatment (up to 24 months) ]
- Phase 2: Overall Response Rate per the Modified Lugano Classification [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months) ]
- Phase 2: Disease Control Rate (DCR) per Lugano Classification 2014 [ Time Frame: Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a CR or PR or stable disease (SD) (up to 6 months) ]
- Phase 2: Duration of Response (DOR) per Lugano Classification 2014 [ Time Frame: Time from the first response of PR or CR until disease progression or death (up to 12 months) ]
- Phase 2: Number of Participants With AEs by Occurrence, Nature, and Severity [ Time Frame: From start of study drug administration up to 30 days after last dose of study treatment (up to 24 months) ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participants greater than or equal to (≥) 18 years of age.
- Pathologically confirmed de novo DLBCL or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma).
-
Prior lines of systemic therapy for the treatment of DLBCL:
- For Arms A, B, C, E, F, H: Participants must have received at least 1 but no more than 3 prior lines of systemic therapy for the treatment of DLBCL.
- For Arm D (S-R-GemOx) participants must have received at least 1 but not more than 2 lines of systemic therapy (Documentation to be provided).
- For Arm G (S-LT) participants must have received only 1 line of systemic therapy
- Positron emission tomography (PET) positive measurable disease per the Lugano Classification 2014, having at least 1 node with longest diameter (LDi) greater than (>) 1.5 centimetres (cm) or 1 extranodal lesion with LDi >1 cm.
- Adequate bone marrow function.
- Circulating lymphocytes less than or equal to (≤) 50 * 109/L.
- Adequate liver and kidney function.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
- An estimated life expectancy of >6 months at Screening.
- Participants with primary refractory disease defined as no response or relapse within 6 months after ending first-line treatment will be allowed on study (up to 20 percentage [%] of enrolled participants in each Phase).
- Male participants and female participants of childbearing potential must agree to use highly effective methods of contraception: Male participants must agree not to donate sperm.
- Participants with active hepatitis B Virus (HBV) are eligible if antiviral therapy for hepatitis B has been given for >8 weeks and viral load is <100 international units per milliliter (IU/mL); participants with hepatitis C Virus (HCV) are eligible if viral load is negative; participants with human immunodeficiency virus (HIV) are eligible if cluster of differentiation 4 (CD4+) T-cell counts ≥350 cells per microliter (cells/μL), viral load is negative and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year.
Exclusion Criteria:
- DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma; composite lymphoma (Hodgkin lymphoma + NHL); Gray zone lymphoma; DLBCL transformed from Chronic Lymphocytic Leukemia (Richter Syndrome); Primary mediastinal large B-cell lymphoma (PMBCL); T-cell rich large B-cell lymphoma.
- Participants with high grade lymphoma with c-MYC, B-cell lymphoma 2 (BCL-2) and/or BCL-6 rearrangements are excluded from the Phase 1 portion of the study only.
- Previous treatment with selinexor or other XPO1 inhibitors.
- Use of any standard or experimental anti-DLBCL therapy (including nonpalliative radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy) <21 days prior to Cycle 1 Day 1 (C1D1). Low dose steroids <30 mg prednisone (or equivalent) are permitted; and palliative radiotherapy.
- Received strong cytochrome P450 3A (CYP3A) inhibitors ≤7 days prior to Day 1 dosing or strong CYP3A inducers ≤14 days prior to Day 1 dosing.
- Major surgery <14 days of C1D1.
- Autologous stem cell transplant (SCT) <100 days or allogeneic SCT <180 days prior to C1D1 or active graft-versus-host disease after allogeneic SCT (or cannot discontinue graft versus host disease [GVHD] treatment or prophylaxis).
-
Prior chimeric antigen receptor T cell (CAR-T cell) infusion at any time (Phase 1 only); prior CAR-T cell infusion ≤120 days prior to C1D1 (Phase 2 only).
The following are Arm Specific exclusion criteria:
- Arm B (S-PR): Serum total bilirubin >1.5 * ULN, Neuropathy Grade ≥2 (CTCAE, v5.0).
- Arm C (S-PBR): Serum total bilirubin >1.5 * ULN, Neuropathy Grade ≥2 (CTCAE, v5.0).
- Arm D (S-R-GemOx): Neuropathy Grade 2≥ (CTCAE, v5.0) interstitial lung disease or pulmonary fibrosis.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04607772
Contacts
| Contact: Jatin Shah, Chief Medical Officer, MD | (617) 658-0600 | jshah@karyopharm.com | |
| Contact: Sharon Shacham, President and Chief Scientific Officer, PhD, MBA | (617) 658-0600 | sshacham@karyopharm.com |
Locations
Show 17 study locations
Sponsors and Collaborators
Karyopharm Therapeutics Inc
| Responsible Party: | Karyopharm Therapeutics Inc |
| ClinicalTrials.gov Identifier: | NCT04607772 |
| Other Study ID Numbers: |
XPORT-DLBCL-025 |
| First Posted: | October 29, 2020 Key Record Dates |
| Last Update Posted: | February 2, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Karyopharm Therapeutics Inc:
|
Karyopharm Diffuse Large B-Cell Lymphoma DLBCL KPT-330 Selinexor Bendamustine Rituximab |
Polatuzumab Vedotin Gemcitabine Oxaliplatin Ibrutinib Lenalidomide Tafasitamab Venetoclax |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Gemcitabine Rituximab Oxaliplatin Lenalidomide Bendamustine Hydrochloride |
Venetoclax Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents |